Open AccessPB2380 PROGNOSTIC EVALUATION OF MULTIPLE MYELOMA PATIENTS SUBMITTED TO UP‐FRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM A SINGLE BRAZILIAN CENTER
Author(s) -
Vivas Y.,
Hungria V.,
Santos K.,
Chaoubah A.,
BustamanteTeixeira M.,
Vivas L.,
Costa L.,
Neto A.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000567984.44895.6a
Subject(s) - medicine , multiple myeloma , context (archaeology) , univariate analysis , hematopoietic stem cell transplantation , multivariate analysis , transplantation , regimen , oncology , single center , induction chemotherapy , autologous stem cell transplantation , surgery , chemotherapy , paleontology , biology
Background: Although autologous hematopoietic stem cell transplantation (AHSCT) has been performed in the context of multiple myeloma since the end of the 90's, response to therapy and patient survival are not homogeneous between different patients. Aims: In order to understand the factors involved in therapy response degree and survival on AHSCT performed as first‐line therapy, we conducted a retrospective analysis of myeloma multiple patients from asingle Brazilian center. Methods: All patients treated with AHSCT between May 2004 and October 2017were evaluated, excluding patients with prior transplant therapies or insufficient records data.Variables related to the International Staging System (ISS), Durie‐Salmon staging, clinical presentation at diagnosis, regimen used for induction, number of treatment cycles, induction and transplant treatment response assessmentwere studied.Event free survival (EFS) and overall survival (OS) were calculated and associated to analyzed factors. Results: Altogether, 137 patients were included in the study, with an average age of 52 years, 59,1% of them were male and 86,9% nonblack. Fifty two patients (38%) died, 6 (4,4%) of these during AHSCT. OS was 63,8% and EFS was 25,1% in 5 years.OS univariate analysis, as confirmed by multivariate analysis, was smaller in patients with anemia at diagnosis (p = 0,006).EFS, submitted to multivariate analysis, was smaller in patients treated with more than one line of induction chemotherapy.A positive response to induction therapy was the main factor related to a very good partial response and complete response to AHSCT (p = 0,001). Summary/Conclusion: Notwithstanding the great gap in knowledge over the successful myeloma multiple AHSCT factors, our data is similar to the ones found in literature, with anemia as an important independent prognostic factor to OS.